Microparticle-mediated VZV propagation and endothelial activation

Mechanism of VZV vasculopathy

Despina Eleftheriou, PhD,* Elena Moraitis, PhD,* Ying Hong, PhD, Mark Turmaine, PhD, Cristina Venturini, PhD, Vijeya Ganesan, MD, Judith Breuer, MD, Nigel Klein, PhD, and Paul Brogan, PhD


Abstract

Objective

Varicella zoster virus (VZV) can spread anterogradely and infect cerebral arteries causing VZV vasculopathy and arterial ischemic stroke. In this study, we tested the hypothesis that virus-infected cerebrovascular fibroblasts undergo phenotypic changes that promote vascular remodeling and facilitate virus transmission in an in vitro model of VZV vasculopathy. The aims of this project were therefore to examine the changes that virus-infected human brain adventitial vascular fibroblasts (HBVAFs) undergo in an in vitro model of VZV vasculopathy and to identify disease biomarkers relating to VZV-related vasculopathy.

Methods

HBVAFs were infected with VZV, and their ability to migrate, proliferate, transdifferentiate, and interact with endothelial cells was studied with flow cytometry. Microparticles (MPs) released from these cells were isolated and imaged with transmission electron microscopy, and their protein content was analyzed with mass spectrometry. Circulating MP profiles were also studied in children with VZV and non-VZV vasculopathy and compared with controls.

Results

VZV-infected HBVAFs transdifferentiated into myofibroblasts with enhanced proliferative and migratory capacity. Interaction of VZV-infected HBVAFs with endothelial cells resulted in endothelial dysfunction. These effects were, in part, mediated by the release of MPs from VZV-infected HBVAFs. These MPs contained VZV virions that could transmit VZV to neighboring cells, highlighting a novel model of VZV cell-to-cell viral dissemination. MPs positive for VZV were significantly higher in children with VZV-related vasculopathy compared to children with non-VZV vasculopathy ($p = 0.01$) and controls ($p = 0.007$).

Conclusions

VZV-infected HBVAFs promote vascular remodeling and facilitate virus transmission. These effects were mediated by the release of apoptotic MPs that could transmit VZV infection to neighboring cells through a Trojan horse means of productive viral infection. VZV+ MPs may represent a disease biomarker worthy of further study.

*These authors contributed equally to this work.

From the Infection, Immunology and Rheumatology Section (D.E., E.M., Y.H., C.V., J.B., N.K., P.B.) and Clinical Neurosciences (V.G.), University College London GOS Institute of Child Health; Arthritis Research UK Centre for Adolescent Rheumatology (D.E.), and Department of Cell and Developmental Biology (M.T.), University College London, UK.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by Versus Arthritis.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Varicella zoster virus (VZV) can spread anterogradely and infect cerebral arteries, causing VZV stroke. Recent histologic studies from VZV-infected brain arteries indicate that human brain vascular adventitial fibroblasts (HBVAFs) are the portal of VZV entry into the cerebral circulation and may be the source of myofibroblasts identified in the intima of VZV-infected cerebral arteries. We examined the changes that these virus-infected cerebrovascular fibroblasts undergo to promote vascular remodeling and facilitate virus transmission in an in vitro model of VZV vasculopathy.

Methods

**VZV culture and viral protein detection**

THA- or green fluorescent protein (GFP)–tagged ORF 23–expressing VZV was grown in MeWo (human melanoma cell line) cells, mitotically inactivated by mitomycin C, and titered by immunohistochemical staining with anti-VZV antibodies. Infected HBVAFs (either VZV or mock) were inoculated to resting HBVAFs at a ratio of 1:3. Infection was confirmed with detection of cytopathic effect and expression of the following viral proteins: envelope glycoprotein H (gH) expressed at 12 to 24 hours after VZV infection and VZV immediate early protein (IE62 protein) expressed at 4 to 12 hours after VZV infection.

HBVAF transdifferentiation and proliferation were assessed with α-smooth muscle actin–APC (R&D Systems, Minneapolis, MN) and Click-iT Plus EdU Alexa Fluor 647 Kit (Invitrogen, Carlsbad, CA). HBVAF migration was assessed using a scratch assay with a 200-μL pipette tip in cells incubated with 10 μg/mL mitomycin C to inhibit mitosis.

CD54-PE (BD Biosciences, East Rutherford, NJ) expression on human umbilical vein endothelial cells (HUVECs [PromoCell, Heidelberg, Germany]) was analyzed by flow cytometry. Intracellular reactive oxygen species (ROS) production was determined as oxidation-dependent fluorescence of dichloro-dihydro-fluorescein diacetate (Molecular Probes, Eugene, OR).

Cytokines were measured with Meso Scale Discovery electrochemiluminescence.
According to current consensus, deafferentation with abnormalities of the arterial wall and categorized arteriopathy was defined as focal or segmental stenosis or occlusion with abnormalities of the arterial wall and categorized according to current consensus definitions. For the 10 patients with non–VZV-related cerebral vasculopathy, the following tests were negative or normal: intrathecal VZV immunoglobulin (Ig) G production, CSF PCR for VZV, and blood test findings. For the 10 patients referred to the neurovascular service at the Great Ormond Street Hospital NHS Foundation Trust, London, UK. Arterial distribution. 3 Cerebral/cervical vasculopathy/ischemic stroke (AIS) was defined as an acute focal neurologic deficit attributable to cerebral infarction in a corresponding arterial distribution. 3 Cerebral/cervical vasculopathy/arteriopathy was defined as focal or segmental stenosis or occlusion with abnormalities of the arterial wall and categorized according to current consensus definitions. 3 For the 10 patients with non–VZV-related cerebral vasculopathy, the following tests were negative or normal: intrathecal VZV immunoglobulin (Ig) G production, CSF PCR for VZV, and blood test investigations (serum IgM and VZV PCR) for acute VZV infection. There was no history of chickenpox in any of these 10 children. Three patients were classified as having VZV vasculopathy on the basis of radiologic evidence of cerebral vasculopathy/arteriopathy and history of VZV infection within 12 months from the acute AIS event and/or positive CSF (VZV PCR or intrathecal VZV IgG) findings. 4 Age-matched healthy controls were children with no AIS, no acute or recent history of VZV infection, or any other vascular pathology (n = 10).

Standard protocol approvals, registrations, and patient consents
This study was approved by the Bloomsbury Ethics Committee, London (07/Q0508/58), and all participants provided consent or age-appropriate assent.

Statistics
Results are expressed as mean and SEM or median and range. Values of p < 0.05 by unpaired t test or Mann-Whitney U test were considered significant.

Data availability
All data are presented within this article and its supplemental material.

Results
First, we confirmed that VZV could infect HBVAFs. Cells were infected/mock infected with either wild-type VZV or GFP-ORF23 VZV. We detected positive expression of GFP-ORF23 and of VZV-related viral proteins gH and VZV IE62 in infected HBVAFs, with no detectable VZV protein or GFP-ORF23 expression in mock-infected cells from day 2 onward.

We observed increased myofibroblast transdifferentiation of VZV-infected HBVAFs compared to mock-infected cells, as indicated by increased expression of a-smooth muscle actin (a myofibroblast surface marker) in VZV-infected HBVAFs at 2 and 6 days after infection (p = 0.04 and p = 0.03, respectively). VZV infection also enhanced proliferation of HBVAFs, as indicated by increased expression of the marker EdU in VZV-infected cells, compared to mock-infected cells at days 2 and 6 (p = 0.03 and p = 0.01, respectively). Significantly more HBVAFs migrated into the marked scratch area of an in vitro scratch assay at 17 hours in the VZV-infected cultures compared to mock-infected cultures (p = 0.01).

Adventitial fibroblasts produce biologically active proteins that affect endothelial function and vasculopathy progression. Therefore, we next examined the interaction of VZV-infected HBVAFs with endothelial cells. Conditioned media from VZV-infected HBVAFs induced significant upregulation of CD54 expression, a marker of endothelial activation, in cultured HUVECs (p = 0.009) and resulted in enhanced ROS production as assessed through oxidation-dependent fluorescence of dichloro-dihydro-fluorescein (p = 0.005). No such changes were observed with media from mock-infected cells.

To further characterize what could be driving this endothelial activation, we profiled cytokine production in the culture supernatant from VZV-infected HBVAF compared to mock-infected cells. These cells released significantly higher levels of cytokines/chemokines that activate endothelium, promote leukocyte adhesion, and enhance fibroblast migration: interleukin-6 (p = 0.02); tumor necrosis factor-α (p = 0.02); interleukin-8 (p = 0.01), and monocyte chemoattractant protein-1 (p = 0.02).

We next investigated signaling between HBVAFs and endothelial cells mediated by cellular MPs. MPs (0.1–1 μm) are released from apoptotic or activated cells and have high surface phosphatidylserine content, which binds annexin V. 3 We identified a significantly higher number of annexin V+ GFP+ ORF23+ MPs in supernatants from cultures of VZV-infected cells compared to mock-infected cells (p = 0.02). These MPs also expressed the VZV protein gH.

Transmission electron microscopy uranyl acetate–negative staining of MPs confirmed the presence of VZV associated with MPs in pellets from VZV-infected cells; these virus particles
were not detected in MP pellets from mock-infected cells (figure, A–D). MPs were identified in the VZV-infected pellets with entrapment of viral particles inside MP membrane coats. Viral particles were discernible in the MP structures and were morphologically distinct with an average size of 80 nm. In contrast, MPs had a size of 100 to 400 nm (figure, D).

Proteomic analysis of MPs derived from VZV-infected HBVAFs revealed proteins consistent with their fibroblastic origin. MPs were highly enriched for VZV proteins that were not detected in the MPs derived from mock-infected samples (figure, E and data available from Dryad, doi.org/10.5061/dryad.466fk4h) and did not express RAB (Ras superfamily of monomeric G) proteins commonly found in endosomes.6

We next tested whether MPs were able to induce productive infection. Cytopathic effect was observed in HBVAFs

<table>
<thead>
<tr>
<th>Patients, age, sex</th>
<th>Clinical presentation</th>
<th>Brain MRI findings</th>
<th>MRA other relevant results</th>
<th>Final diagnosis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1, 9 y/M</td>
<td>Vision loss and left transient hemiparesis</td>
<td>Multiple right PCA infarcts</td>
<td>Right vertebral artery dissection</td>
<td>Vertebral artery dissection</td>
<td>Aspirin; warfarin</td>
</tr>
<tr>
<td>Patient 2, 4 y/M</td>
<td>Right-sided hemiparesis</td>
<td>Left basal ganglia infarction</td>
<td>Focal stenosis left MCA</td>
<td>FCA</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Patient 3, 8 y/F</td>
<td>Quadrantanopia headaches</td>
<td>Left PCA infarct</td>
<td>Focal stenosis of left PCA</td>
<td>FCA</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Patient 4, 4 y/M</td>
<td>Left hemiparesis</td>
<td>Right basal ganglia infarct</td>
<td>Focal stenosis right MCA</td>
<td>FCA</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Patient 5, 12 y/F</td>
<td>Right upper limb weakness Dysphasia Headaches</td>
<td>Multifocal bilateral gray and white matter infarcts</td>
<td>Occlusive arteriopathy of ICAs and right vertebral Artery</td>
<td>Unclassified noninfectious arteriopathy</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Patient 6, 7 y/F</td>
<td>Left-sided hemiparesis</td>
<td>Right basal ganglia infarct</td>
<td>Focal stenosis proximal right MCA</td>
<td>FCA</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Patient 7, 5 y/F</td>
<td>Right-sided weakness</td>
<td>Left basal ganglia infarct</td>
<td>Focal stenosis left MCA</td>
<td>FCA</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Patient 8, 13 y/F</td>
<td>Left hemiparesis Choreathetoid movements</td>
<td>Right basal ganglia infarct</td>
<td>Focal stenosis right MCA</td>
<td>FCA</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Patient 9, 11 y/M</td>
<td>Recurrent TIA's</td>
<td>Multifocal bilateral gray and white matter infarcts</td>
<td>Occlusive arteriopathy involving left ACA/ MCA, R ICA</td>
<td>Unclassified noninfectious arteriopathy</td>
<td>Aspirin; warfarin</td>
</tr>
<tr>
<td>Patient 10, 3 y/M</td>
<td>Left-sided hemiparesis</td>
<td>Right basal ganglia infarct</td>
<td>Focal stenosis right MCA</td>
<td>FCA</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Patient 11, 9 years/F</td>
<td>Headaches, R hemiparesis, poor coordination History of VZV infection in past 6 mo</td>
<td>Patchy infarcts in left MCA territory</td>
<td>Left MCA stenosis; intrathecal VZV IgG production (1,636 mIU/mL) and positive VZV PCR (CT = 40) in CSF</td>
<td>VZV related vasculopathy</td>
<td>Aspirin, warfarin; prednisolone, aciclovir</td>
</tr>
<tr>
<td>Patient 12, 5 y/M</td>
<td>Headaches and right-sided hemiparesis History of VZV infection in past 6 mo</td>
<td>Left basal ganglia infarct</td>
<td>Focal stenosis proximal left MCA; positive intrathecal VZV IgG production (4,029 mIU/mL); CSF VZV PCR negative</td>
<td>VZV related vasculopathy</td>
<td>Aspirin, aciclovir</td>
</tr>
<tr>
<td>Patient 13, 6 y/M</td>
<td>Dystonic left-sided hemiparesis Preceding history of VZV infection in past 3 mo</td>
<td>R basal ganglia infarct</td>
<td>Focal stenosis proximal right MCA CSF studies not available</td>
<td>VZV-related vasculopathy</td>
<td>Aspirin Treatment with aciclovir considered but not started due to parental preference</td>
</tr>
</tbody>
</table>

Abbreviations: ACA = anterior cerebral artery; AIS = arterial ischaemic stroke; FCA = focal cerebral arteriopathy of childhood; ICA = internal carotid artery; IgG = immunoglobulin G; MCA = middle cerebral artery; MRA = magnetic resonance angiography; PCA = posterior circulation artery; VZV = varicella zoster virus. The first 10 patients described in the table below with non-VZV related cerebral vasculopathy tested negative for intrathecal VZV IgG production, CSF PCR for VZV, blood test investigations for acute VZV infection and had no preceding history of chickenpox. For VZV CSF IgG normal range <15 mIU/mL. Prednisolone was given at 2 mg/kg/d and reduced over 6–8 weeks. Aspirin was administered at 5 mg/kg/d. Aciclovir was given intravenously for 3 weeks (60-30 mg/kg/dose/d) followed by oral aciclovir (20 mg/kg/dose 4 times a day) for further 6 months.
incubated with MPs derived from VZV-infected cells using both phase-contrast and fluorescent microscopy, with detection of green fluorescence representing GFP-ORF23 VZV. No fluorescence was detected in HBVAFs incubated with MPs from mock-infected HBVAFs (figure, F and G). The addition of heparin, an inhibitor of cell free virus entry to the cells, made no difference in the infection efficiency observed, providing evidence that the infection was mediated by MP-VZV complexes, not free VZV. MPs from infected HBVAFs were also able to activate endothelium, as demonstrated by higher

**Figure** VZV induces release of MPs that contain VZV particles

(A–D) Transmission electron microscopy images of microparticle (MP) pellet obtained at 135,000× and 95,000× magnification. Scale bar 100 nm. (A) MP shed by mock-infected human brain adventitial vascular fibroblast (HBVAF) that appears collapsed and donut shaped (diameter 100 nm). (B) MP (arrow) harvested from varicella zoster virus (VZV)–infected HBVAF closely associated with a viral particle. (C) MP with a diameter of 400 nm includes a viral envelope as a central spherical structure of ~80-nm diameter with surface spikes. (D) Free VZV particle with 80-nm diameter, penetrated by the stain, with the appearance of a hexagon with surface projections (viral nucleocapsid). No envelope was identified outlining the nucleocapsid. (E) Proteins identified by liquid chromatography–mass spectrometry in MP from control mock-infected HBVAF and from VZV-infected HBVAF. (F and G) MP induced VZV infection in cultures of HBVAF shown with both phase-contrast and fluorescent microscopy and with no such changes in control. (H and I) Incubation of endothelial cells with MP induced upregulation of CD54 expression (p = 0.001) and reactive oxygen species, determined as oxidation-dependent fluorescence of dichloro-dihydro-fluorescein diacetate (DCFH-DA, p = 0.0002). Results are expressed as mean and SEM; p values were calculated by the unpaired t test. (K) Higher numbers of AnV+ VZV- glycoprotein H+ MPs were detected in the circulation of children with VZV-related vasculopathy compared to children with other vasculopathies (p = 0.01) and controls (p = 0.007). Results are expressed as median and range; p values were calculated by Mann-Whitney U test. AnV = Annexin V; MFI = mean fluorescent intensity.
induction of CD54 expression ($p = 0.001$) and higher ROS production ($p = 0.002$) in HUVECs compared to MPs from mock-infected HBVAF (figure, H and I).

Lastly, we explored VZV-MP complexes in the circulation of children with AIS and VZV-related cerebral vasculopathy, children with cerebral vasculopathy not associated with antecedent VZV, and healthy age-matched controls. Total annexin V+ MP levels were higher in children with VZV vasculopathy ($n = 3$) compared to healthy controls ($n = 10, p = 0.007$) but did not differ from total annexin V+ MP levels detected in patients with non–VZV-related cerebral vasculopathy ($n = 10$). When corrected for the detection of VZV gH protein, however, a signifi
copathy ($n = 10$). When costained for the detection of VZV
detected in patients with non-
 neurological cargo acquired from their cells of origin to antigen-
delivery of antigens derived from the bi-
logical cargo acquired from their cells of origin to antigen-
spreading cells to abrogate early immune responses to viral
invasion. This may not apply just to MPs; alternative cellular
microvesicle populations (such as endosomes) may also play
a role. Moreover, whether MP-mediated viral propagation is
specific to VZV or also applies to other viruses causing AIS
requires further investigation. It would also be interesting to
establish whether VZV-infected cells release phenotypically
and quantitatively distinct MPs in resting, activated, and
apoptotic states.

The small size of our clinical study with a few cases with VZV
vasculopathy precludes any definitive conclusions about our
proposed mechanism in patients but does at least provide
some preliminary face validity regarding our model in a
clinical context for this rare disease. Although applied to
a pediatric cohort here, the detection of MP-VZV complexes
might also be an approach that is diagnostically useful for
adult patients, in whom establishing a diagnosis of VZV
vasculopathy can be equally challenging. Thus, while the
diagnostic or prognostic relevance of circulating VZV+ MPs
is currently unknown, study of this as a potential novel
biomarker could be fruitful. This would require a prospective
study of large numbers of patients, with or without vascul-
opathy, and further characterization of the cellular origin of
these circulating MP-VZV complexes. It would also be in-
teresting to use sensitive assays such as fluorescent antibody
to membrane antigen and VZV-IgG time-resolved
fluorescence immunoassay to quantify varicella antibodies
in patients with VZV vasculopathy and correlate them with
levels of VZV MPs.

While challenging in a rare disease setting in which patient
numbers are limited, further insights might be obtained by
exploring our model in more complex 3-D in vitro tissue cul-
ture systems. This might unveil novel druggable targets for
VZV vasculopathy.

**Study funding**

Dr. Eleftheriou and Dr. Hong were supported by Arthritis
Research UK (grants 20164, 21593, and 21791). Professor
Brogan is supported by the Great Ormond Street Hospital
(GOSH) Children’s Charity. All authors acknowledge the
National Institute of Health Research (NIHR) Biomedical
Research Centre at GOSH. The views expressed are those of
the authors and not necessarily those of the NHS, NIHR, or
Department of Health.

**Disclosure**

D. Eleftheriou has received institutional grants and consult-
sancy fees from Pfizer, Lilly, and Roche. E. Moraitis, Y. Hong,
M. Turmaine, C. Venturini, V. Ganesan, J. Breuer, and N.
Klein report no disclosures relevant to the manuscript. P.
Brogan has received institutional grants and/or consultancy
fees from Roche, Novoimmuno, Novartis, SOBI, Nov-
immune, and UCB. Go to Neurology.org/N for full
disclosures.

**Publication history**

Received by Neurology March 14, 2019. Accepted in final form
August 20, 2019.

**Appendix Authors**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Despina Eleftheriou, PhD</td>
<td>University College</td>
<td>Corresponding author</td>
<td>Design and conceptualized study, analyzed and interpreted the data, drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td></td>
<td>London, UL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elena Moraitis, PhD</td>
<td>University College</td>
<td>Author</td>
<td>Major role in the acquisition of data, analyzed data, revised manuscript</td>
</tr>
<tr>
<td></td>
<td>London, UL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ying Hong, PhD</td>
<td>University College</td>
<td>Author</td>
<td>Major role in the acquisition of data, interpreted the data, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td></td>
<td>London, UL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**References**


**Appendix**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Turmaine, PhD</td>
<td>University College London, UL</td>
<td>Author</td>
<td>Acquisition of data and data analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Cristina Venturini, PhD</td>
<td>University College London, UL</td>
<td>Author</td>
<td>Acquisition of data and data analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Vijaya Ganesan, PhD</td>
<td>University College London, UL</td>
<td>Author</td>
<td>Acquisition of data and data analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Judith Breuer, PhD</td>
<td>University College London, UL</td>
<td>Author</td>
<td>Acquisition of data and data analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Nigel Klein, PhD</td>
<td>University College London, UL</td>
<td>Author</td>
<td>Acquisition of data and data analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Paul Brogan, PhD</td>
<td>University College London, UL</td>
<td>Author</td>
<td>Design and conceptualized study, analyzed and interpreted the data, drafted the manuscript for intellectual content</td>
</tr>
</tbody>
</table>
Microparticle-mediated VZV propagation and endothelial activation: Mechanism of VZV vasculopathy
Despina Eleftheriou, Elena Moraitis, Ying Hong, et al.
_Neurology_ published online December 31, 2019
DOI 10.1212/WNL.0000000000008885

This information is current as of December 31, 2019

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/early/2019/12/31/WNL.0000000000008885.full

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Cerebrovascular disease/Stroke
http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke
All Pediatric
http://n.neurology.org/cgi/collection/all_pediatric
Other cerebrovascular disease/ Stroke
http://n.neurology.org/cgi/collection/other_cerebrovascular_disease__stroke
Pediatric stroke; see Cerebrovascular Disease/ Childhood stroke
http://n.neurology.org/cgi/collection/pediatric_strokeSee_cerebrovascular_disease-childhood_stroke
Viral infections
http://n.neurology.org/cgi/collection/viral_infections

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise